Experimental vaccine forces bacteria down an evolutionary dead end

  14 June 2021

In the world of bacteria and viruses, drugs and vaccines are the environmental pressures that they must overcome. And they do it with frustrating ease, quickly finding ways around the attacks and then swapping those genes like trading cards. The end result is the constant looming threat of antibiotic-resistant “superbugs” that render our best drugs ineffective.

So the researchers at ETH Zurich set out to turn this strength into a weakness. Rather than developing a drug that kills bacteria, the team wanted to find a way to funnel its evolution down a path where it becomes weaker, and less of a problem for the host.

Further reading: New Atlas
Author(s): Michael Irving
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support kindly provided by

Antimicrobial Resistance Fighter Coalition

CDD VAULT Complexity Simplified





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!